Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

Vernon Bernardino has given his Buy rating due to a combination of factors, including promising preliminary results from Citius Pharmaceuticals’ ongoing clinical trial of Lymphir in combination with ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for trea ...

Results also showed a two-year progression-free survival rate of 48% with Keytruda compared with 19% with chemotherapy. There was also an improved overall response rate with Keytruda of 43.8% ...

Either preoperative chemoradiotherapy or preoperative/perioperative chemotherapy can be recommended to patients with esophageal or gastroesophageal junction cancer ...

The Phase 3 trial (STAR-121) is appraising the combo against Keytruda + chemo with a third arm of zim + chemo, randomized 4:4:1. The primary endpoints are OS and PFS with key secondary endpoints ...

In patients with negative PD-L1 expression (CPS <1) in Cohort B, efti in combination with KEYTRUDA&circledR; achieved a 35.5% objective response rate (ORR). This is among the highest recorded for a ...

This approach could avoid the side effects that often occur when chemotherapy is given intravenously, and the synergistic effect of the two therapies may extend the patient's lifespan longer than ...

3A or 3B non-small cell lung cancer whose disease did not completely respond to neoadjuvant Keytruda plus platinum-based chemotherapy. Global recruitment has also started for this trial, with the ...

She had radiation, chemotherapy and surgery to remove the ... Her last treatment in 2020 was Keytruda, a prescription immunotherapy drug used to treat many types of cancer. Gemberling is currently ...

To be eligible for the trial, patients must have stage II, IIIA, or IIIB NSCLC and have not achieved pathological complete response after neoadjuvant Keytruda plus chemotherapy and surgical resection.